CRBP Company Profile and Key Details

Corbus Pharmaceuticals Holdings, Inc. has 19.34 million shares outstanding. The public float is 15.16 million shares, elevated short interest at 14.17% of float. This equals 2.30 million shares. The short ratio is 7.4 days. Institutional investors hold 71.91% of the float. Insiders own 1.08%. Cormorant Asset Management, LP holds 2.34 million shares, White Barbara has 206.22 thousand shares and Cohen Yuval has 157.32 thousand shares. Over the past six months, insider transactions show net selling. They sold 38.24 thousand shares across 5 transactions.

CRBP has shown mixed momentum, gaining 7.51% over the past week and -55.54% over the past quarter, though year-to-date performance is up 5.53%. Short-term trend indicators are bullishly aligned (SMA20 5.46%, SMA50 0.97%, SMA200 -16.59%). The stock’s 14-day RSI is 54.22 (neutral), while the ATR of 0.5 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -59.87% below its high and over 77.8% above its low. Average 10-day trading volume of 662.73 thousand shares is slightly above the 3-month average of 454.18 thousand, indicating heightened recent market interest.

Corbus Pharmaceuticals Holdings, Inc. generated EPS of -$5.51 over the past year. Five-year average earnings growth is 35.71%. Wall Street analysts project EPS growth of -12.92% annually over the next five years. The latest quarter delivered EPS of -$1.81. The next quarter is forecast at -$1.52. Next year's EPS is expected at $40.09. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $57.00 to $30.00. The high target offers 591.75% upside. The low target suggests 264.08% downside. The mean target is $43.21. This offers 424.39% upside. Corbus Pharmaceuticals Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by 43.65%. The prior quarter beat by -2.38%. Over the last six quarters, Apple has recorded several small beats. These include 10.32% in May 06, 2025.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) closed at $8.24 USD, losing -$0.62 (-7.00%) from the previous close of $8.86. The stock is currently mid-range between its 52-week high and low $7.12 and $20.56. With a market capitalization of about $152.67 million, Corbus Pharmaceuticals Holdings, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.64). Key stats such as the average daily volume over the past year has been around 454.55 thousand shares, in line with its 52-week average. Headquartered in Norwood, MA, Corbus Pharmaceuticals Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Yuval Cohen, the company employs approximately 36 people and listed since October 27, 2014. Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) shares are flat 5.53% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Corbus Pharmaceuticals Holdings, Inc. trading at a premium to the broader market with a P/E of -1.28. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $43.81, suggesting 431.67% upside. Our AI forecast model points to short-term strength (27.31% over two weeks), a medium-term rise (53.28% over three months), and a longer-term loss (-59.95% over one year), with expected trading ranges indicating moderate volatility.

Corbus Pharmaceuticals Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.02. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that Corbus Pharmaceuticals Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 27.31%, with price expected at $10.49 by September 23, 2026, within a range of $10.05 to $10.95 3-Month Outlook: Projected rise of 53.28%, reaching $12.63 by December 08, 2026, with a range of $11.48 to $13.39. 1-Year Outlook: Projected loss of -59.95%, with price at $3.30 by September 09, 2027, within a range of $0.00 to $0.00.

Corbus Pharmaceuticals Holdings, Inc. trades at a P/E ratio of -1.28, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.57 suggesting the stock is closer to book value. The P/FCF stands at -1.77, also below market averages.